Chemical Abstract, vol. 113, No. 17, Oct. 22, 1990, (Columbus, Ohio, US) M. Laurikka-Routti et al.: "A contraceptive vaginal ring releasing ethinyl estradio and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry". |
Chemical Abstract, vol. 102, No. 21, May 27, 1985, (Columbus, Ohio, US) Viveca Odlind et al.: "ST-1435. Development of an implant". |
Knepp et al., "Transermal Drug Delivery: Problems and Possibilities," CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 4, Issue 1, pp. 13-37 (1987). |
Pannatier, et al., "The Skin as a Drug Metabilizing Organ," Drug Metabolism Reviews, vol. 8, No. 2, pp. 319-343 (1978). |
Nathke, et al., "Transdermal Delivery of Levonorgesttrel," Proceedings of 13th International Symposium on Controlled Release of Bioactive Materials, Chaudry and Thies, eds., The Controlled Release Society, Inc., pp. 29-30 (1986). |
Friend, David R., "Transdermal Delivery of Levonorgestrel," Medicianl Research Reviews, vol. 11, No. 1, 049-080 (1991). |
Haukkamaa, Maija; Laurikka-Routti, Marjut and Heikinheimo, Oskari, "Transdermal Absorption of the Progestin ST-1435: Therapeutic Serum Steroid Concentrations and High Excretion of the Steroid in Saliva," Contraception, vol. 44, No. 3, pp. 269-276 (1991). |